Teva Pharmaceutical Industries Limited (TEVJF)
| Previous close | 11.75 |
| Open | 11.75 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 11.75 - 11.75 |
| 52-week range | 7.03 - 15.87 |
| Volume | |
| Avg. volume | 1,908 |
| Market cap | 15.7B |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 28 Nov 2017 |
| 1y target est | N/A |
Insider MonkeyCorcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript May 1, 2024 Corcept Therapeutics Incorporated beats earnings expectations. Reported EPS is $0.2503, expectations were $0.21. Corcept Therapeutics Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank […]
Business WireTeva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
TEL AVIV, Israel, May 02, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2023 Healthy Future Report, sharing its actions to promote healthy people, a healthy planet and a healthy business. The report unveils new targets to achieve net zero emissions across Teva’s operations and value chain by 2045 and 100% renewable electricity across all Teva sites by 2035, as well as to reach 200% more total beneficiaries of health system strengthening and capacity building
- Thomson Reuters StreetEvents
Q1 2024 Corcept Therapeutics Inc Earnings Call
Q1 2024 Corcept Therapeutics Inc Earnings Call
